PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.
作者信息
Melani Christopher, Major Ajay, Schowinsky Jeffrey, Roschewski Mark, Pittaluga Stefania, Jaffe Elaine S, Pack Svetlana D, Abdullaev Zied, Ahlman Mark A, Kwak Jennifer J, Morgan Rustain, Rabinovitch Rachel, Pan Zenggang, Haverkos Bradley M, Gutman Jonathan A, Pollyea Daniel A, Smith Clayton A, Wilson Wyndham H, Kamdar Manali
机构信息
National Cancer Institute, Bethesda, MD.
University of Colorado School of Medicine, Aurora, CO.
出版信息
N Engl J Med. 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767.
Abstract
摘要
相似文献
1
PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.纵隔灰色地带淋巴瘤中的程序性死亡受体1阻断疗法
N Engl J Med. 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767.
2
[Not Available].[无可用内容]
Bull Cancer. 2016 Nov;103 Suppl 1:S160-S163. doi: 10.1016/S0007-4551(16)30374-5.
3
Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.接受大剂量化疗和干细胞移植后复发的铂难治性生殖细胞癌男性患者对抗程序性细胞死亡蛋白1抗体的反应
Eur J Cancer. 2017 May;76:1-7. doi: 10.1016/j.ejca.2017.01.033. Epub 2017 Mar 4.
4
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.帕博利珠单抗在复发/难治性原发性纵隔大B细胞淋巴瘤患者中的安全性和耐受性。
Blood. 2017 Jul 20;130(3):267-270. doi: 10.1182/blood-2016-12-758383. Epub 2017 May 10.
5
PD-1 Blockers.PD-1 抑制剂。
Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.
6
Targeting immune checkpoints in lymphoma.靶向淋巴瘤中的免疫检查点。
Curr Opin Hematol. 2015 Jul;22(4):337-42. doi: 10.1097/MOH.0000000000000158.
7
Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.识别和治疗多发性骨髓瘤和淋巴瘤中检查点抑制剂治疗的候选者。
Expert Rev Hematol. 2020 Apr;13(4):375-392. doi: 10.1080/17474086.2020.1733405. Epub 2020 Mar 2.
8
PD-1 inhibitors effective in hodgkin lymphoma.PD-1抑制剂对霍奇金淋巴瘤有效。
Cancer Discov. 2015 Feb;5(2):102-3. doi: 10.1158/2159-8290.CD-NB2015-002. Epub 2015 Jan 9.
9
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.复发/难治性淋巴瘤患者接受PD-1阻断治疗后进行异基因造血干细胞移植的安全性和有效性
Blood. 2017 Mar 9;129(10):1380-1388. doi: 10.1182/blood-2016-09-738385. Epub 2017 Jan 10.
10
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.恶性淋巴瘤中的PD-1-PD-L1免疫检查点阻断
Ann Hematol. 2018 Feb;97(2):229-237. doi: 10.1007/s00277-017-3176-6. Epub 2017 Nov 11.
引用本文的文献
1
Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies.用于治疗血液系统恶性肿瘤的基于抗体的免疫疗法
Cancers (Basel). 2024 Dec 15;16(24):4181. doi: 10.3390/cancers16244181.
2
A targeted gene signature stratifying mediastinal gray zone lymphoma into classical Hodgkin lymphoma-like or primary mediastinal B-cell lymphoma-like subtypes.一种将纵隔灰色地带淋巴瘤分层为经典型霍奇金淋巴瘤样或原发性纵隔B细胞淋巴瘤样亚型的靶向基因特征。
Haematologica. 2024 Nov 1;109(11):3771-3775. doi: 10.3324/haematol.2024.285266.
3
Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma.全国性研究中晚期儿童恶性肿瘤的抗PD-1治疗：皮肤黑色素瘤和霍奇金淋巴瘤疗效良好
Cancers (Basel). 2024 Feb 28;16(5):968. doi: 10.3390/cancers16050968.
4
Evolution of Lymphoma Diagnosis in the Era of Personalized Medicine: A Marriage of Pathology and Genomics for Clinical Practice.个性化医学时代的淋巴瘤诊断演变：病理学与基因组学在临床实践中的结合。
Am J Pathol. 2023 Dec;193(12):1880-1886. doi: 10.1016/j.ajpath.2023.08.012. Epub 2023 Sep 19.
5
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.帕博利珠单抗联合伏立诺他治疗复发/难治性 B 细胞非霍奇金淋巴瘤的 I 期临床试验结果。
Haematologica. 2024 Feb 1;109(2):533-542. doi: 10.3324/haematol.2023.283002.
6
[Gray zone lymphoma: five cases report and literature review].[灰色地带淋巴瘤：5例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):242-246. doi: 10.3760/cma.j.issn.0253-2727.2023.03.011.
7
Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment.淋巴瘤中免疫检查点抑制的耐药机制：聚焦肿瘤微环境
Front Pharmacol. 2023 Mar 7;14:1079924. doi: 10.3389/fphar.2023.1079924. eCollection 2023.
8
Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma.肿瘤微环境对检查点阻断治疗的贡献：霍奇金淋巴瘤的经验教训。
Blood. 2023 May 4;141(18):2187-2193. doi: 10.1182/blood.2022016590.
9
Zr Immuno-PET Imaging of Tumor PD-1 Reveals That PMA Upregulates Lymphoma PD-1 through NFB and JNK Signaling.Zr 免疫 PET 成像肿瘤 PD-1 揭示 PMA 通过 NF-κB 和 JNK 信号上调淋巴瘤 PD-1。
Mol Imaging. 2022 Feb 12;2022:5916692. doi: 10.1155/2022/5916692. eCollection 2022.
10
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma.弥漫性大 B 细胞淋巴瘤中肿瘤细胞状态和生态系统的景观。
Cancer Cell. 2021 Oct 11;39(10):1422-1437.e10. doi: 10.1016/j.ccell.2021.08.011. Epub 2021 Sep 30.
本文引用的文献
1
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.程序性死亡配体1（PD-L1）和程序性死亡配体2（PD-L2）基因改变可定义经典型霍奇金淋巴瘤并预测预后。
J Clin Oncol. 2016 Aug 10;34(23):2690-7. doi: 10.1200/JCO.2016.66.4482. Epub 2016 Apr 11.
2
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.纳武利尤单抗治疗复发或难治性霍奇金淋巴瘤的 PD-1 阻断作用。
N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.
3
A prospective study of mediastinal gray-zone lymphoma.纵隔灰色地带淋巴瘤的前瞻性研究。
Blood. 2014 Sep 4;124(10):1563-9. doi: 10.1182/blood-2014-03-564906. Epub 2014 Jul 14.
4
Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations.灰区淋巴瘤：染色体异常与免疫表型和临床相关性。
Mod Pathol. 2011 Dec;24(12):1586-97. doi: 10.1038/modpathol.2011.116. Epub 2011 Aug 5.
5
Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.纵隔灰色地带淋巴瘤：经典霍奇金淋巴瘤与纵隔大B细胞淋巴瘤之间缺失的环节。
Am J Surg Pathol. 2005 Nov;29(11):1411-21. doi: 10.1097/01.pas.0000180856.74572.73.
Zotero 插件